Phase III, randomised, open-label, active-controlled, multicentre, parallel-group study to assess the non-inferior antiviral activity and safety of a two-drug regimen of dolutegravir and lamivudine compared to continuation on a TAF-based regimen in HIV-infected adults who are virologically suppressed and stable on a TAF-based regimen.

Trial Profile

Phase III, randomised, open-label, active-controlled, multicentre, parallel-group study to assess the non-inferior antiviral activity and safety of a two-drug regimen of dolutegravir and lamivudine compared to continuation on a TAF-based regimen in HIV-infected adults who are virologically suppressed and stable on a TAF-based regimen.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Feb 2018

At a glance

  • Drugs Dolutegravir (Primary) ; Lamivudine
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms TANGO
  • Most Recent Events

    • 13 Feb 2018 New trial record
    • 08 Feb 2018 According to a GlaxoSmithKline media release, results are expected in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top